Above the 40 (November 7, 2018) – Exclamation Points for the End of Oversold Trading Conditions

AT40 = 40.5% of stocks are trading above their respective 40-day moving averages (DMAs) AT200 = 37.4% of stocks are trading above their respective 200DMAs VIX = 16.4 Short-term Trading Call: bullish Commentary Financial markets made their votes very clear after the U.S. 2018 midterm election. via GIPHY Apparently, today’s rally in the S&P 500 … Read more

Above the 40 (August 17, 2018) – Another Picture-Perfect Rebound Ends Stretched Conditions

AT40 = 55.4% of stocks are trading above their respective 40-day moving averages (DMAs) AT200 = 56.7% of stocks are trading above their respective 200DMAs VIX = 12.6 Short-term Trading Call: neutral Commentary The recovery from the February swoon has been full of nearly predictable bounces: whether it was oversold trading conditions or support at … Read more

Above the 40 (October 6, 2017) – Stock Market Lift-Off

AT40 = 73.8% of stocks are trading above their respective 40-day moving averages (DMAs) – overbought day #7 AT200 = 59.7% of stocks are trading above their respective 200DMAs VIX = 9.7 Short-term Trading Call: bullish Commentary This is what a lift-off for an extended overbought rally looks like. The S&P 500 (SPY) followed its … Read more

Above the 40 (September 11, 2017) – The S&P 500 Hits Fresh All-Time High On Tension Relief

AT40 = 53.0% of stocks are trading above their respective 40-day moving averages (DMAs) AT200 = 51.1% of stocks are trading above their respective 200DMAs VIX = 10.7 (down 11.5%) Short-term Trading Call: neutral (see below for caveats) Commentary I had no idea that the previous tensions in the stock market fully priced in the … Read more

Allergan Signals Higher Prices Potentially Ahead for Teva Pharmaceuticals

Teva Pharmaceuticals (TEVA) lost 24% last Thursday after reporting disappointing earnings. From the Seeking Alpha transcript of the conference call: “All of us at Teva understand the frustration and disappointment our shareholders are feeling… In our U.S. Generics business, we experienced accelerated price erosion and decreased volume, mainly due to customer consolidation, greater competition as … Read more